Skip to search formSkip to main contentSkip to account menu

SB 204269

Known as: SB-204269 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2001
2001
The effects of tonabersat (SB‐220453) were evaluated on trigeminal nerve ganglion stimulation‐induced sensory‐autonomic… 
2000
2000
1998
1998
On December 3, 1998, the Society for Medicines Research held a meeting entitled Trends in Medicinal Chemistry at the National… 
1998
1998
  • F. Crespi
  • IDrugs : the investigational drugs journal
  • 1998
  • Corpus ID: 1653794
SB-204269 is an anticonvulsant agent under development by SmithKline Beecham, It is in phase II clinical trials as a potential… 
1997
1997
1 Earlier optimization of structure‐activity relationships in a novel series of 4‐(benzoylamino)‐benzopyrans, led to the… 
1997
1997
1 SB‐204269 (trans‐(+)‐6‐acetyl‐4S‐(4‐fluorobenzoylamino)‐3,4‐dihydro‐2,2‐dimethyl‐2H‐benzol[b]pyran‐3R‐ol, hemihydrate) shows… 
1997
1997
Departments of Neurosciences Research and*Medicinal Chemistry, SmithKline Beecham Pharmaceuticals, NewFrontiersSciencePark…